FIGURE 5.
EGFR pathway‐independent resistance mechanisms in patients who developed acquired resistance to EGFR‐TKIs. (a) Incidence of small cell lung cancer transformation between gefitinib/erlotinib/afatinib and osimertinib. (b) KRAS mutation incidence between gefitinib/erlotinib/afatinib and osimertinib. (c) MET amplification incidence between gefitinib/erlotinib/afatinib and osimertinib. (d) PIK3A mutation incidence between gefitinib/erlotinib/afatinib and osimertinib